Consensus Haemonetics Corporation

Stocks

HAE

US4050241003

Medical Equipment, Supplies & Distribution

Market Closed - NYSE 00:00:03 04/09/2026 +04			5-day change	1st Jan Change
102.85 ^USD	-0.07%		-3.52%	+28.32%

08-19	Barrington Raises Price Target on Haemonetics to $118 From $95, Keeps Outperform Rating	MT
08-18	Haemonetics Shares Rise After Signing Supply Agreement With CSL Plasma	MT

Evolution of the Average Target: Haemonetics Corporation

Evolution of the Target Price: Haemonetics Corporation

Changes in Analyst Recommendations: Haemonetics Corporation

4d6a74e77cfba7bd38ce07a9.90YUm9OPeh5T8A-Skggzm3ipRNRVCS_Xd-He64jjHl8.pHNAzozKHGsHgVXn2XkByBz-c7k3PXifJJm9u_mCUjzOLSb1ttkdQTu6aA~f2cc5214a8410a172e62102f165df627

Analysts' recommendations: Haemonetics Corporation

08-19	Barrington Raises Price Target on Haemonetics to $118 From $95, Keeps Outperform Rating	MT
08-13	BofA Securities Adjusts Price Target on Haemonetics to $100 From $93	MT
08-12	BofA Securities Adjusts Haemonetics Price Target to $100 From $93	MT
08-07	Barrington Research Adjusts Haemonetics PT to $95 From $89, Maintains Outperform Rating	MT
05-22	Haemonetics Likely to See Upside as Core Businesses Improve, BofA Securities Says	MT
05-22	BofA Securities Upgrades Haemonetics to Buy From Neutral, Price Target is $80	MT
05-12	Barrington Cuts Price Target on Haemonetics to $89 From $94, Keeps Outperform Rating	MT
01-12	Barrington Adjusts Price Target on Haemonetics to $93 From $90, Maintains Outperform Rating	MT
12-15	Needham Downgrades Haemonetics to Hold From Buy, Removes $78 Price Target	MT
12-11	Citigroup Downgrades Haemonetics to Neutral From Buy, Adjusts PT to $88 From $77	MT
11-07	Haemonetics Taking Prudent View on Guidance After Plasma Recovery, BofA Says	MT
11-07	BofA Securities Upgrades Haemonetics to Neutral From Underperform, Raises Price Target to $75 From $58	MT
11-07	Needham Raises Price Target on Haemonetics to $78 From $68, Keeps Buy Rating	MT
11/08/25	Haemonetics Shares Fall After Raymond James Downgrade	MT
11/08/25	Raymond James Downgrades Haemonetics to Outperform From Strong Buy	MT
08/08/25	Haemonetics Shares Fall After JPMorgan Downgrade	MT
08/08/25	Needham Cuts Price Target on Haemonetics to $68 From $84, Keeps Buy Rating	MT
08/08/25	JPMorgan Downgrades Haemonetics to Neutral From Overweight, Adjusts Price Target to $62 From $85	MT
09/07/25	Haemonetics Shares Rise After Upgrade From Citigroup	MT
09/07/25	Citigroup Upgrades Haemonetics to Buy From Neutral, Lifts Price Target to $90 From $71	MT
09/07/25	Analyst recommendations: Illumina, Freeport-McMoran, XPO, T-Mobile US…
26/06/25	Baird Initiates Coverage on Haemonetics With Outperform Rating, $87 Price Target	MT
18/03/25	Needham Trims Price Target on Haemonetics to $104 From $108, Keeps Buy Rating	MT
06/12/24	JPMorgan Initiates Haemonetics at Overweight With $116 Price Target	MT
10/09/24	BTIG Initiates Haemonetics at Buy With $112 Price Target	MT

More recommendations

Other Medical Equipment, Supplies & Distribution

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	HAEMONETICS CORPORATION					+3.38%
	ABBOTT LABORATORIES					+8.81%
	MEDTRONIC PLC					+12.22%
	CENCORA, INC.					+9.8%
	HOYA CORPORATION					+25.58%
	BECTON, DICKINSON AND COMPANY					+4.34%
	DEXCOM, INC.					+4.94%
	MEDLINE INC.					+22.86%
	WEST PHARMACEUTICAL SERVICES, INC.					+18.13%
	TERUMO CORPORATION					+26.9%
	Average					+13.70%
	Weighted average by Cap.					+12.23%